title: Suppression of TH17-mediated pathology through BET bromodomain inhibition.
abstract: Epigenetic control of gene expression is enforced in part through histone modifications. Bromodomain and extra terminal domain (BET) proteins function as crucial chromatin readers, responsible for interpretation of the chromatin code in diverse cellular contexts, ultimately impacting gene transcription. BET proteins can play a major role in inflammation by profoundly affecting the biology of the Thelper17 (TH17) lineage. We summarize recent studies focusing on BET inhibition as a viable therapeutic alternative for the control of autoimmune diseases driven by aberrant activation of TH17 cells.
authors: Constellation Pharmaceuticals, 215 First Street, Cambridge, MA, United States. Electronic address: srimoyee.ghosh@constellationpharma.com.
authors: Srimoyee
authors: S
authors: Ghosh
authors: Constellation Pharmaceuticals, 215 First Street, Cambridge, MA, United States. Electronic address: jose.lora@constellationpharma.com.
authors: Jose M
authors: JM
authors: Lora
mesh_terms: D000818:Animals; D002454:Cell Differentiation; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D000072417:Protein Domains; D058504:Th17 Cells / Q000166:cytology / Q000378:metabolism*; D014157:Transcription Factors / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism
chemical_list: D016207:Cytokines; D009687:Nuclear Proteins; D014157:Transcription Factors